• First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
• DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
• Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.